Kylie Keijzer on Muck Rack

Kylie Keijzer

As seen in: Nature, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kylie

Contact Kylie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study | Nature Communications

|
By Kylie Keijzer, Adrienne H. Brouwers, Joyce van Sluis, Frank R. Pierik, Arjan Diepstra, Sjoerd G. Elias
| Nature
Correction to: Nature Communications https://doi.org/10.1038/s41467-025-66767-9, published online 25 November 2025 In the version of the article initially published, in the “Post-CART”, “Cohort 2” section of Fig. 1b, the “89ZED88082A PET/CT” icon was on the “D7” dashed line but should have been on the “D5” dashed line. The figure has now been corrected in the HTML and PDF versions of the article.
Open in Who Shared View Duplicates (2) Issue with article?

Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study - Nature Communications

|
By Kylie Keijzer, Adrienne H. Brouwers, Joyce van Sluis, Frank R. Pierik, Arjan Diepstra, Sjoerd G. Elias
| Nature
Abstract Chimeric antigen receptor T-cell therapy (CART) has revolutionized the treatment of patients with refractory/relapsed large B-cell lymphoma (R/R LBCL). Limited biopsy data indicate that a higher activated CD8+ T-cell density is associated with tumor response. However, tumor biopsies fail to capture the systemic kinetics of CD8+ T-cells.
Open in Who Shared Issue with article?

Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma | Blood Cancer Journal

|
By Kylie Keijzer, Tom van Meerten
| Nature
Abstract Bridging therapy before CD19-directed chimeric antigen receptor (CAR) T-cell infusion is frequently applied in patients with relapsed or refractory Large B-cell lymphoma (r/r LBCL). This study aimed to assess the influence of quantified MATV and MATV-dynamics, between pre-apheresis (baseline) and pre-lymphodepleting chemotherapy (pre-LD) MATV, on CAR T-cell outcomes and toxicities in patients with r/r LBCL.
Open in Who Shared Issue with article?
See all 4 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Kylie

Contact Kylie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified